Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 19/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.67 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.67 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.60 |
| ▸ | F2 | P00734 | 1/20 | 0.60 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2364390 | 0.89 | F10 (0.75) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL12490259 | 0.89 | F10 (0.80) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL12493717 | 0.83 | F10 (1.00) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL14838697 | 0.82 | F10 (0.82) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL14838628 | 0.82 | F10 (0.81) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL15180492 | 0.82 | F10 (0.81) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL13584317 | 0.81 | F10 (0.66) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL8226210 | 0.80 | F10 (0.68) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL15846795 | 0.80 | CYP1A2 (1.00) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL392956 | 0.80 | F10 (0.78) | F10CYP1A2CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2521723-A1 | PROCESS FOR THE PREPARATION OF RIVAROXABAN AND INTERMEDIATES THEREOF | Enantia, S.L. (ES) | 2012-11-14 | — | — | EP | disclosed |
| US-20120283434-A1 | PROCESS FOR THE PREPARATION OF RIVAROXABAN AND INTERMEDIATES THEREOF | ENANTIA, S.L. (ES) | 2012-11-08 | — | — | US | disclosed |
| WO-2011080341-A1 | PROCESS FOR THE PREPARATION OF RIVAROXABAN AND INTERMEDIATES THEREOF | ENANTIA, S.L. (ES) | 2011-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283434-A1 | PROCESS FOR THE PREPARATION OF RIVAROXABAN AND INTERMEDIATES THEREOF | F12, VKORC1, CYP2C9 | F10 4/4885CYP1A2 24/4885CYP3A4 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.